Consent Form - Emmes

The purpose of this study is to provide you with a new investigational chemotherapy drug, Compound 506U78, which is not yet commercially available to you for treatment. Compound 506U78 has been found to have activity (that is, cause remissions) in a limited number of other patients with T-cell leukemia/lymphoma. ................
................